Enalare Therapeutics Expands Its Scientific Workforce With Appointment of Thomas Miller, PhD, as Vice President of Medical Improvement

Enalare Therapeutics Inc., a biopharmaceutical firm devoted to growing novel therapies for sufferers affected by life-threatening important care situations, introduced immediately that it has expanded its scientific crew with the appointment of Thomas Miller, Ph.D., as Vice President of Medical Improvement.

Dr. Miller brings greater than 20 years of expertise within the improvement of biophysical and pharmacological interventions focused primarily at important care pulmonary operate and attenuation of ventilator-induced lung harm. Miller is effectively revealed with an tutorial background within the preclinical and medical improvement of novel gadget and drug therapies. He transitioned to business because the pioneer of high-velocity nasal insufflation, which is now a world front-line normal of look after respiratory insufficiency. For the final 14 years, Tom has been main medical improvement for medical applied sciences, most lately as Govt Vice President of Medical & Regulatory Affairs for Vixiar Medical, targeted on a novel platform to assess pulmonary hemodynamics secondary to situations resembling coronary heart failure.

“I’m tremendously excited to hitch the Enalare crew and assist drive the event of our novel lead drug candidate ENA-001 for acute respiratory despair. That is an alternative to make a serious distinction in look after a number of affected person populations having a transparent unmet want,” said Miller. “Enalare is growing a one-of-a-kind remedy and it is work that comes with a fantastic sense of function.”

“We’re thrilled to have somebody of Tom’s medical {and professional} experience be a part of our rising group,” said Herm Cukier, Enalare’s President and CEO. “His expertise with pulmonary applied sciences will probably be a valued complement to our already excellent scientific crew as we pursue improvement of a number of merchandise with our agnostic respiratory stimulant expertise.”

“We’re excited to have Dr. Miller be a part of the Enalare Workforce. His background enhances the path of our strategic focus,” said Dr. Joseph Pergolizzi, Enalare’s Head of Analysis & Improvement. “I am assured that he’ll make vital contributions to our improvement actions.”

Previous to his function at Vixiar, Tom established and led medical and scientific affairs globally for Vapotherm, taking part in a big scientific function throughout the firm’s path to an IPO. He beforehand directed a translational analysis program at Nemours (A.I. duPont Hospital for Kids) and holds a school place with the Sidney Kimmel Medical School at Thomas Jefferson College. Dr. Miller acquired his Ph.D. in Medical Physiology from the Lewis Katz College of Medication at Temple College, an MS in Kinesiology from Temple College and a BS from the College of Delaware.

About Enalare Therapeutics Inc.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical firm devoted to growing novel therapies for sufferers affected by life-threatening important care situations, together with drug overdose, post-surgery respiratory despair, and apnea of prematurity. The Firm introduced a partnership with BARDA earlier this yr for the event of its lead compound ENA-001 as a Medical Countermeasure for mass casualty occasions.



Morgan Wagner

Enalare Investor Relations


Supply: Enalare Therapeutics Inc.